iCAD announces new real-world clinical evidence on ProFound AI

iCAD announced new real-world clinical evidence to be presented at the European Congress of Radiology, ECR, 2023 meeting confirms ProFound AI boosts radiologists’ efficiency and accuracy. The Company is also showcasing its Breast AI Suite of deep-learning breast cancer detection, density assessment and risk evaluation tools in booth #AI-14 at the meeting, which is taking place in Vienna from March 1-5. "iCAD‘s comprehensive suite of breast AI solutions offers clinically proven benefits to clinicians and patients alike," said Stacey Stevens, President and CEO of iCAD, Inc. "A growing number of leading imaging facilities worldwide trust our technologies to detect cancer and stop it in its tracks – streamlining workflow, improving accuracy, and personalizing results like never before." In a research presentation session on Friday, March 3 from 16:00-17:30 CET, Kathy Schilling, MD, Medical Director, Christine E. Lynn Women’s Health & Wellness Institute, Boca Raton Regional Hospital, USA, will present findings from a study titled "Real-world breast cancer screening performance with digital breast tomosynthesis before and after implementation of an artificial intelligence detection system."